Skip to search formSkip to main contentSkip to account menu
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease
TLDR
The differential diagnostic significance of the 14-3-3 immunoblot is similar to that of the tau-protein ELISA, and for patients with type II prion protein and methionine/valine or valine/Valine polymorphism at codon 129, t Tau-protein has a higher diagnostic sensitivity than 14- 3-3 protein.
View on Publisher
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
TLDR
Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients and their value as prognostic markers should be investigated further.
View on Publisher
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
TLDR
Serum NFL is increased in ALS in comparison to other conditions and can serve as diagnostic and prognostic biomarker and establish a cut-off level for the diagnosis of ALS.
View on BMJ
14-3-3 adaptor proteins recruit AID to 5′-AGCT-3′-rich switch regions for class switch recombination
TLDR
14-3-3 proteins specifically bound 5′-AGCT-3′ repeats, were upregulated in B cells undergoing CSR and were recruited with AID to the switch regions that are involved in CSR events (Sμ→Sγ1, Sμ→ Sγ3 or S μ→Sα).
View on Nature
Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis
TLDR
Blood and CSF neurofilament levels are linked to the symptomatic phase of ALS and might serve as objective markers of structural damage to the nervous system.
View on Wiley
Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease.
TLDR
CSF of patients with Alzheimer's disease, patients with Creutzfeldt-Jakob disease, and non-demented control patients shows that GFAP and S-100B represent astroglial markers and the different levels of these proteins in CSF of AD and CJD patients might point to a distinct pathophysiological involvement in these diseases.
View on PubMed
Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease
TLDR
Follow-up CSF analyses are of limited value for the differentiation of AD and DLB and it is concluded that more specific markers have to be established for the differentiate and follow-up of these diseases.
View on Springer
Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression
TLDR
CHIT1 could be a potentially useful marker for differential diagnosis and prediction of disease progression in ALS and, therefore, seems suitable as a supplemental marker for patient stratification in therapeutic trials.
View on BMJ
Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis
TLDR
The data suggest that a deficiency of cellular neuroprotective mechanisms (decrease of sAPP) is linked to progressive neuro-axonal damage (increase of NfHSMI35) and to progression of disease.
View PDF
Beta-Amlyoid 1–42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinson’s Disease Dementia
TLDR
It is suggested that such protein CSF changes may help to support the clinical diagnosis of cognitive decline in PD and that there may be apolipoprotein-E-isoform-specific differences in CSF protein regulation in advanced PDD.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License